Shilpa Medicare rallied 10% after the CEO confirmed that the company had the capacity to manufacture 100-200 million doses of COVID vaccines. Shilpa has not confirmed if it would work with AstraZeneca or RDIF for Sputnik-V vaccine.
Both vaccines are based on recombinant technology combining DNA from a virus with bacterial cells to produce purified proteins so capacity is flexible. Shilpa manufactures APIs, which are pharma inputs, and it can manufacture vaccines at its Dharwad facility.
Shilpa Medicare rallied 10% after the CEO confirmed that the company had the capacity to manufacture 100-200 million doses of COVID vaccines. Shilpa has not confirmed if it would work with AstraZeneca or RDIF for Sputnik-V vaccine.
Both vaccines are based on recombinant technology combining DNA from a virus with bacterial cells to produce purified proteins so capacity is flexible. Shilpa manufactures APIs, which are pharma inputs, and it can manufacture vaccines at its Dharwad facility.